FIRST LIGHT

30 October 2024

RESEARCH

CIPLA | TARGET: Rs 1,312 | -11% | SELL

No meaningful incremental triggers until Goa plant clearance

MARICO | TARGET: Rs 695 | +10% | HOLD

Urban stable, rural growing

JK CEMENT | TARGET: Rs 4,190 | -4% | HOLD

Steady performance despite challenges; maintain HOLD

GREENPLY INDUSTRIES | TARGET: Rs 380 | +7% | HOLD

Weak Q2 result on MDF margin pressure

SOMANY CERAMICS | TARGET: Rs 850 | +30% | BUY

Guidance lowered on weak H1; positive medium-term outlook

GREENPANEL INDUSTRIES | TARGET: Rs 365 | -3% | HOLD

Dismal Q2; MDF margin bottoms out, but recovery to take time

SUMMARY

CIPLA

- Earnings in line with our estimates on all fronts. However, US sales was down and 5% lower than our estimates in rupee terms
- US sales (CC) guided for less than US$ 220mn due to Lanreotide supply issue in Q3FY25. Market share expected to be below 20%
- gAdvair launch to be delayed further, we downgrade the stock to SELL, roll our valuations to Sep'26, with a new TP of Rs 1,312 (from Rs 1,560)

Click here **for the full report.**

BOBCAPS Research
research@bobcaps.in

MARICO

- Versus consensus, sales miss 1%, EBITDA miss 2% on 15bps lower-than-expected margins. Parachute volumes +4% vs retail offtake +8%
- Rural recovery remains intact while urban is stable. On cost, vegetable oil and copra inflation are being passed on in a calibrated manner
- SETU continues to impact visibility on volumes and margin outlook is uncertain over the next 2-3 quarters. Retain HOLD

Click here for the full report.

JK CEMENT

- Grey cement volumes at 3.8mt (excluding clinker volumes) fell by ~3% YoY (-12% QoQ) owing to weak demand impacted by seasonality
- EBITDA fell 39% YoY to ~Rs 2.8bn, EBITDA margin fell sharply YoY to 11.6% on higher other expenses and logistics cost
- We trim FY25E/FY26E/FY27E EBITDA by 14%/10%/4%, value JKCE at 14x 1Y forward EV/EBITDA and lower TP to Rs 4,190. Maintain HOLD

Click here for the full report.

GREENPLY INDUSTRIES

- Topline broadly in line; but sharp miss on EBITDA due to steep sequential contraction in MDF margin (-487bps QoQ to 11.8%)
- Maintained volume guidance for plywood (+8-10%) and MDF (+50%) for FY25; MDF margin guided to improve to 16%/18% in FY25/FY26
- Maintain HOLD with revised TP of Rs 380 as bright future prospects are already baked into the current valuation

Click here for the full report.

SOMANY CERAMICS

- Topline broadly in line; but EBITDA missed on margin contraction due to low absorption of fixed-cost overhead
- Guidance lowered as volume targeted to grow in mid-single digit (vs low double digit) with flat margin (+1.0%-1.5%) for FY25
- Maintain BUY with revised TP of Rs 850 on strong earnings growth prospects with improvement in ROE profile and reasonable valuations

Click here for the full report.

GREENPANEL INDUSTRIES

- Sharp contraction in GREENP EBITDA (-57% YoY) for eight straight quarters on supply overhang in MDF industry
- Downgrade MDF volume and margin guidance based on weak H1FY25 performance
- Worst is over, but we maintain HOLD with unchanged TP of Rs 365 in anticipation of gradual recovery in MDF sector margin

Click here for the full report.

RESULT REVIEW

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

SELL
TP: Rs 1,312 | ∀ 11%

CIPLA | Pharmaceuticals | 30 October 2024

No meaningful incremental triggers until Goa plant clearance

- **Earnings in line with our estimates on all fronts. However, US sales was down and 5% lower than our estimates in rupee terms**
- **US sales (CC) guided for less than US$ 220mn due to Lanreotide supply issue in Q3FY25. Market share expected to be below 20%**
- **gAdvair launch to be delayed further, we downgrade the stock to SELL, roll our valuations to Sep'26, with a new TP of Rs 1,312 (from Rs 1,560)**

Foram Parekh
research@bobcaps.in

Earnings in line with estimates: CIPLA reported an in-line set of earnings, with reported sales/EBITDA 1.6%/0.6% above our estimates and PAT -0.2% below our estimates. EBITDA margin was 30bps lower than our estimate of 26.7%.

North America region sales to slow down: CIPLA's US sales in Q2 was 5% lower than our estimate of Rs 19.8bn and in constant currency (CC) terms at US$ 236mn. Sales was impacted by (1) temporary supply issues in Lanreotide, (2) 10% YoY price erosion pressure in the base portfolio (30% of portfolio) and (3) flat gRevlimid sales on a sequential basis. Lanreotide's supply issues are expected to resume from Q4FY25, thus lowering Q3FY25 sales in CC terms to US$ 220mn. Subsequently, we have lowered US sales by 4% to Rs 77.9bn for FY25e. CIPLA's key product launch gAdvair is expected to be delayed further as the Goa plant has received six observations from the USFDA inspection recently.

Domestic growth to be lower than industry average: During Q2FY25, domestic sales grew by 5% below Indian Pharma Market (IPM) growth due to lower traction in the Anti-Infective segment, affecting both branded generic prescription and trade generics. We believe that while CIPLA would continue to grow at IPM levels of 8-9%, it would underperform its industry peers – growing at 11-12%.

H2FY25 margins to be lower than H1FY25: CIPLA reported 26.2% EBITDA margin in H1FY25, but management maintained its earlier FY25 guidance of 24.5-25.5%. We believe CIPLA will report lower EBITDA margin in H2FY25 as (1) domestic sales is expected to grow in the single digit, (2) Lanreotide sales is likely to be affected by supply issues in the North America region, and (3) growth in the South Africa region is unlikely to drive margins as they are lower than company-level margins.

Downgrade to SELL; TP cut to Rs 1,312: We downgrade to SELL due to (1) lower US sales, (2) tender base growth in the South Africa region and (3) no clarity on Goa plant clearance affecting the gAdvair launch. Hence, we ascribe a lower P/E of 20x, and roll forward our valuations to Sep'26, with new TP of Rs 1,312 (from Rs 1,560).

Key changes

Target	Rating
▼	▼

Ticker/Price	CIPLA IN/Rs 1,478
Market cap	US$ 14.2bn
Free float	65%
3M ADV	US$ 30.5mn
52wk high/low	Rs 1,702/Rs 1,165
Promoter/FPI/DII	33%/26%/24%

Source: NSE | Price as of 29 Oct 2024

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	257,741	267,084	287,281
EBITDA (Rs mn)	62,911	66,611	73,185
Adj. net profit (Rs mn)	43,164	44,931	49,570
Adj. EPS (Rs)	53.6	55.8	61.5
Consensus EPS (Rs)	53.6	57.4	64.1
Adj. ROAE (%)	17.5	15.8	15.2
Adj. P/E (x)	27.6	26.5	24.0
EV/EBITDA (x)	18.4	17.2	15.3
Adj. EPS growth (%)	44.6	4.1	10.3

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

RESULT REVIEW

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

HOLD
TP: Rs 695 | ▲ 10%

MARICO | Consumer Staples | 30 October 2024

Urban stable, rural growing

- **Versus consensus, sales miss 1%, EBITDA miss 2% on 15bps lower-than-expected margins. Parachute volumes +4% vs retail offtake +8%**
- **Rural recovery remains intact while urban is stable. On cost, vegetable oil and copra inflation are being passed on in a calibrated manner**
- **SETU continues to impact visibility on volumes and margin outlook is uncertain over the next 2-3 quarters. Retain HOLD**

Lokesh Gusain
research@bobcaps.in

Broadly in-line result: MRCO reported 5% underlying EBITDA growth despite 8% sales growth as EBITDA margin contracted 50bps to 19.6%. Compared to Bloomberg consensus, sales were 1% below both our and consensus estimates, while EBITDA 2% below consensus and in line with our estimate.

Pricing versus inflation: MRCO has taken 15% pricing in vegetable oils and is comfortable on elasticity. The demand sensitive band starts from Rs 200/pk while the company is currently at Rs 185/pk. Further pricing is required and will be taken in a calibrated manner. The company is guiding for a 40-50bps hit to FY25 margins. We think the margin percentage impact may be lower due to the combination of elasticity being in control over time, and inflation being a nationwide phenomenon.

SETU impact on volumes remains unpredictable but December quarter may provide some insights: In 2QFY25, Parachute volumes grew +4% vs measured retail offtake at +8%. MRCO indicated continued stock adjustments based on the pace of growth in direct and its impact on the sales in indirect channel. Shipments will align with retail offtake in two quarters. The December quarter should provide more clarity between stock adjustments and the extent of incremental changes in retail demand. Meanwhile, four more states were added to Project SETU, bringing the total to ten. The project is progressing to plan in terms of outlets expansion.

Earnings outlook: Our sales forecast is unchanged for FY25 – initial volume response may be weak until all players are onboard with pricing. For FY26, our sales forecasts are slightly higher with EBITDA up in line as pricing comes through. FY27 is largely unchanged.

Valuation and our view: FMCG is rational with inflation passed through in a phased manner. Margin hit near term but stabilisation over the next two quarters. Even then, Project SETU-driven unpredictability on sales growth is uncharacteristic of an FMCG company. Bangladesh also needs more evidence of smooth repatriation. We continue to use the P/E rel method, valuing MRCO in line with its historical average. At 49x P/E 12M to Sep'26, we derive our Rs 695 TP. HOLD.

Key changes

Target	Rating
▲	◄ ►

Ticker/Price	MRCO IN/Rs 629
Market cap	US$ 9.7bn
Free float	40%
3M ADV	US$ 19.2mn
52wk high/low	Rs 720/Rs 486
Promoter/FPI/DII	59%/25%/16%

Source: NSE | Price as of 29 Oct 2024

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	96,530	107,106	118,868
EBITDA (Rs mn)	20,260	22,101	24,655
Adj. net profit (Rs mn)	14,810	16,072	17,730
Adj. EPS (Rs)	11.5	12.5	13.7
Consensus EPS (Rs)	11.5	12.8	14.4
Adj. ROAE (%)	36.5	36.6	36.5
Adj. P/E (x)	54.8	50.5	45.8
EV/EBITDA (x)	40.1	36.7	32.9
Adj. EPS growth (%)	13.7	8.5	10.3

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

RESULT REVIEW

HOLD

TP: Rs 4,190 | ⋎ 4%

JK CEMENT | Cement | 30 October 2024

Steady performance despite challenges; maintain HOLD

- **Grey cement volumes at 3.8mt (excluding clinker volumes) fell by ~3% YoY (-12% QoQ) owing to weak demand impacted by seasonality**
- **EBITDA fell 39% YoY to ~Rs 2.8bn, EBITDA margin fell sharply YoY to 11.6% on higher other expenses and logistics cost**
- **We trim FY25E/FY26E/FY27E EBITDA by 14%/10%/4%, value JKCE at 14x 1Y forward EV/EBITDA and lower TP to Rs 4,190. Maintain HOLD**

Milind Raginwar
research@bobcaps.in

Topline performance impacted by tepid volume; realisation stays weak: JKCE reported 7%/10% YoY/QoQ fall in revenues to ~Rs 23.9bn in Q2FY25 largely dragged by tepid grey cement volume growth and weak realisations. Grey cement volumes at 3.8mt (excluding clinker volumes) fell by ~3% YoY (-12% QoQ) due to listless demand in JKCE's key region of operations in North and Central India. Grey cement realisation too fell by ~6% YoY to Rs 4,706/t indicating weak demand.

Cost inflation impacts margins YoY: The overall cost inflated 3%/10% YoY/QoQ to Rs 5,044/t, attributed to the higher logistic cost which jumped by 10%/2% YoY/QoQ to Rs 1,278/t due to higher lead distance and lower rail mix. Other expenditure leaped by 10%/24% YoY/QoQ to Rs 4.8bn due to maintenance shut down and expenses incurred on other value add products. Energy cost savings only partially offset overall inflation. The blended proportion was ~70% in Q2FY25.

Cost inflation and realisation weakness impact EBITDA/margins: EBITDA fell 39%43% YoY/QoQ) to ~Rs 2.7bn and EBITDA margin by 600bps YoY due to overall cost inflation YoY combined with weak realisations. The aggregate EBITDA/t fell sharply to Rs 649 a fall of ~36% YoY/QoQ.

Expansion plans on track: Prayagraj (GU) has already been commissioned and contributed 83k mnt of cement in the first month of its operations. JKCE's previously-announced 3.3mnt grey clinker line-II at Panna and 3mnt grinding unit in Bihar and 1mnt each in Hamirpur, Prayagraj and Panna (3mnt) are on track to be completed by Q3/Q4FY26.

Retain valuations and maintain HOLD: We trim our FY25/FY26/FY27 EBITDA estimates by 15%/10%/4% due to weakness in the demand and supply hangover. Effectively, the EBITDA/PAT CAGR is now at 21%/20% over FY24-27E. JKCE's focus remains on long-term growth with timely capex and is healthy, while improving earnings quality and reducing balance sheet stress are key. We continue to value JKCE at 14x 1Y forward EV/EBITDA to arrive at a lower TP of Rs 4,190 (from Rs 4,431) and maintain HOLD.

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	JKCE IN/Rs 4,350
Market cap	US$ 4.0bn
Free float	54%
3M ADV	US$ 6.9mn
52wk high/low	Rs 4,896/Rs 3,065
Promoter/FPI/DII	46%/16%/22%

Source: NSE | Price as of 29 Oct 2024

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	1,05,632	1,17,825	1,37,490
EBITDA (Rs mn)	16,502	18,841	23,755
Adj. net profit (Rs mn)	8,361	8,960	11,776
Adj. EPS (Rs)	108.2	116.0	152.4
Consensus EPS (Rs)	108.2	125.1	158.0
Adj. ROAE (%)	17.2	15.9	18.0
Adj. P/E (x)	40.2	37.5	28.5
EV/EBITDA (x)	23.1	20.5	12.2
Adj. EPS growth (%)	48.6	7.2	31.4

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

HOLD

TP: Rs 380 | 7%

GREENPLY INDUSTRIES | Building Materials | 29 October 2024

Weak Q2 result on MDF margin pressure

- **Topline broadly in line; but sharp miss on EBITDA due to steep sequential contraction in MDF margin (-487bps QoQ to 11.8%)**
- **Maintained volume guidance for plywood (+8-10%) and MDF (+50%) for FY25; MDF margin guided to improve to 16%/18% in FY25/FY26**
- **Maintain HOLD with revised TP of Rs 380 as bright future prospects are already baked into the current valuation**

Utkarsh Nopany
research@bobcaps.in

Weak quarter: MTLM missed our estimate for Q2FY25 (revenue/EBITDA/APAT: -2%/-15%/-55%) mainly due to sharp sequential contraction in MDF segment margin (-487bps QoQ to 11.8%). Overall, MTLM's revenue/EBITDA grew by 13%/19% YoY in Q2FY25 over a low base, but APAT was down 23% YoY in Q2FY25 due to the negative contribution from its new furniture fittings JV business. On a 5Y CAGR basis, MTLM EBITDA grew at a nominal 5% CAGR in Q2FY25.

Key highlights: Plywood EBITDA grew by 17.9% YoY in Q2FY25 driven by higher volumes (+5.8% YoY) and improved margin (+153bps YoY to 8.3% on a low base). MDF EBITDA grew by 24.9% YoY in Q2FY25 as higher volumes (+30.7%) more than offset the impact of lower margin (-154bps YoY to 11.8%).

Guidance: MTLM maintained its volume growth guidance for plywood (at 8-10%) and MDF (at 50%) YoY for FY25. The company expects plywood margin to improve to 10% range over the medium term and MDF margin to improve to 16%/18% in FY25/FY26. The furniture fittings division (Phase I) is expected to become fully operational from Nov'24 and Phase II is expected to be completed by Dec'25. The furniture fittings division revenue is expected to be Rs 4bn-5bn in the next three years in the best-case scenario.

Maintain HOLD; TP cut by 5% to Rs 380: We remain positive on MTLM's long-term prospects as we see strong earnings growth prospect (EPS to grow at a healthy 44% CAGR over FY24-FY27E) along with sharp improvement in ROE profile (from 10.7% in FY24 to 18.9% in FY27E). However, we maintain HOLD as we believe its bright prospects are baked well into current valuations (trades at 29.0x on 1Y forward P/E vs. 5Y average of 23.0x). We have cut our TP to Rs 380 (Rs 400 earlier) due to the downward revision of our EPS estimates (-6.1%/-9.1%/-5.5% for FY25E/FY26E/FY27E) based on a weak Q2FY25 result. Our target P/E remains unchanged at 25x on Sep'26 (Jun'26 earlier).

Key changes

Target	Rating
▼	◄ ►

Ticker/Price	MTLM IN/Rs 355
Market cap	US$ 522.9mn
Free float	48%
3M ADV	US$ 2.3mn
52wk high/low	Rs 412/Rs 157
Promoter/FPI/DII	52%/6%/31%

Source: NSE | Price as of 29 Oct 2024

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	21,799	25,321	29,777
EBITDA (Rs mn)	1,875	2,519	3,323
Adj. net profit (Rs mn)	757	1,199	1,744
Adj. EPS (Rs)	6.1	9.7	14.1
Consensus EPS (Rs)	6.1	10.9	15.1
Adj. ROAE (%)	11.2	15.6	19.2
Adj. P/E (x)	58.0	36.6	25.2
EV/EBITDA (x)	21.3	15.2	11.8
Adj. EPS growth (%)	(26.7)	58.4	45.4

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

BUY
TP: Rs 850 | 30%

SOMANY CERAMICS | Building Materials | 29 October 2024

Guidance lowered on weak H1; positive medium-term outlook

- **Topline broadly in line; but EBITDA missed on margin contraction due to low absorption of fixed-cost overhead**
- **Guidance lowered as volume targeted to grow in mid-single digit (vs low double digit) with flat margin (+1.0%-1.5%) for FY25**
- **Maintain BUY with revised TP of Rs 850 on strong earnings growth prospects with improvement in ROE profile and reasonable valuations**

Utkarsh Nopany
research@bobcaps.in

Mixed Q2: SOMC's topline was broadly in line with our estimate (+1.7% YoY to Rs 6.7bn vs Rs 6.5bn estimated), but it missed our EBITDA estimate by 7.6% due to weak margin (-138bps YoY to 8.4% vs 9.3% estimated). Overall, SOMC's EBITDA/APAT fell by 12.7%/41.5% YoY in Q2FY25.

Key highlights: SOMC tiles volume grew by 2.6% YoY (5Y CAGR: +7.2%) in Q2FY25. Tiles realisation was relatively flat (-0.2% QoQ) in a difficult market environment due to improved product mix (GVT share up 100bps QoQ to 38%). EBITDA margin was down 138bps YoY to 8.4% in Q2FY25 mainly due to low absorption of fixed-cost overhead (operating rate down from 89% in Q2FY24 to 77% in Q2FY25). Net debt was relatively stable on QoQ basis at Rs 2.67bn in Sep'24.

Guidance downgrade: SOMC has lowered its volume growth guidance to +5.0-6.5% YoY (vs low double-digit rate) with flat EBITDA margin (vs +1.0-1.5% YoY) for FY25. Management expects the medium-term outlook to remain positive in anticipation of good recovery in tiles demand from the real estate sector and margin profile to improve with the ramp up of the newly-commissioned Max plant. The Max plant continued to operate at a sub-optimal rate of 36% in Q2FY25, but the company expects the plant to operate at a better rate in H2FY25 (which would aid in improving its margin profile in the near future). The company targets to increase the share of project business from 20% in FY24 to 25% in FY25.

Maintain BUY; TP cut by 6% to Rs 850: We maintain our BUY rating on the stock as we see (a) strong earnings growth prospects (EPS to log 19% CAGR over FY24-FY27E) along with improvement in ROE profile (from 11.5% in FY24 to 15.2% in FY27E); and (b) reasonable valuation (trades at 22.9x on 1Y forward P/E vs. 5Y average of 25.2x). We have cut our TP to Rs 850 (Rs 900 earlier) due to the downward revision of our EPS estimates (-15.4%/-2.5%/-1.6% for FY25E/FY26E/FY27E) based on the weak Q2FY25 result. Our target P/E remains unchanged at 25x on Sep'26 estimate (Jun'26 earlier).

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	SOMC IN/Rs 653
Market cap	US$ 318.7mn
Free float	45%
3M ADV	US$ 0.3mn
52wk high/low	Rs 873/Rs 561
Promoter/FPI/DII	55%/2%/24%

Source: NSE | Price as of 29 Oct 2024

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	25,914	26,404	29,529
EBITDA (Rs mn)	2,544	2,458	3,109
Adj. net profit (Rs mn)	991	876	1,382
Adj. EPS (Rs)	24.2	21.4	33.7
Consensus EPS (Rs)	24.2	29.7	39.8
Adj. ROAE (%)	11.5	10.1	14.3
Adj. P/E (x)	27.0	30.6	19.4
EV/EBITDA (x)	9.4	9.8	7.9
Adj. EPS growth (%)	38.1	(11.6)	57.7

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

HOLD
TP: Rs 365 | ⩔ 3%

GREENPANEL INDUSTRIES | Building Materials | 29 October 2024

Dismal Q2; MDF margin bottoms out, but recovery to take time

- **Sharp contraction in GREENP EBITDA (-57% YoY) for eight straight quarters on supply overhang in MDF industry**
- **Downgrade MDF volume and margin guidance based on weak H1FY25 performance**
- **Worst is over, but we maintain HOLD with unchanged TP of Rs 365 in anticipation of gradual recovery in MDF sector margin**

Utkarsh Nopany
research@bobcaps.in

Dismal Q2FY25: GREENP missed our estimates for Q2FY25 (Revenue/EBITDA/ APAT: -9%/-32%/-56%) mainly due to lower MDF sales volume (-18% YoY vs -3% estimated) as it preferred to maintain pricing discipline by sacrificing market share. Overall, GREENP Revenue/EBITDA/APAT fell by 16%/57%/76% YoY in Q2FY25.

Key highlights: GREENP reported sharp YoY contraction in operating profit for the eighth consecutive quarter due to supply overhang in the MDF industry. MDF segment EBITDA de-grew by 57% YoY in Q2FY25 driven by lower volumes (-17.9% YoY) as well as margin contraction (-129bps QoQ to 9.9%). MDF margin fell below the level seen in the previous bear cycle (14.5% in FY19). The plywood segment reported a sharp volume decline for the ninth consecutive quarter (-10.4% YoY) due to internal restructuring and exit from decorative veneer business.

Guidance: The company targets its domestic MDF volume to grow at 15-18% YoY in H2FY25 and 35% YoY in FY26. Exports volume is expected to be in the range of 6K-7K CBM per month in H2FY25. MDF EBITDA margin is expected to improve by 150-200bps in H2FY25 over Q2FY25 and further improvement of 150-200bps in FY26. The company plans to add 231,000 CBM of MDF capacity at its existing Andhra Pradesh plant at a cost of Rs 6bn by Q3FY25.

MDF industry dynamics: Management believes the sharp increase in domestic MDF capacity (from 2.5mn CBM in FY23 to 4.1mn CBM in FY25E vs domestic demand of 2.6mn-2.7mn CBM in FY24) is likely to get absorbed over the next three years as domestic demand is anticipated to grow at 14-16% rate per annum.

Maintain HOLD with unchanged TP of Rs 365: While we believe the worst is over for the Indian MDF industry, we maintain our HOLD rating on the GREENP stock in anticipation of gradual recovery in MDF sector margin. We cut our EPS estimates (-22.6%/-13.5%/-9.4% for FY25E/FY26E/FY27E), but we have kept our TP unchanged at Rs 365 due to roll forward of our valuation from Jun'26 to Sep'26. At CMP, the stock trades at 34.8x on 1Y forward P/E vs. the 5Y average of 24.2x. Our target P/E remains unchanged at 20x.

Key changes

Target	Rating
◄►	◄►

Ticker/Price	GREENP IN/Rs 375
Market cap	US$ 546.5mn
Free float	47%
3M ADV	US$ 1.6mn
52wk high/low	Rs 450/Rs 268
Promoter/FPI/DII	53%/3%/28%

Source: NSE | Price as of 29 Oct 2024

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	15,673	16,123	20,772
EBITDA (Rs mn)	2,465	1,710	3,120
Adj. net profit (Rs mn)	1,428	834	1,664
Adj. EPS (Rs)	11.6	6.8	13.6
Consensus EPS (Rs)	11.6	9.4	17.1
Adj. ROAE (%)	11.4	6.2	11.5
Adj. P/E (x)	32.2	55.0	27.6
EV/EBITDA (x)	18.9	27.3	14.4
Adj. EPS growth (%)	(43.4)	(41.6)	99.4

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**
Brand Name: **BOBCAPS**
Trade Name: **www.barodaetrade.com**
CIN: **U65999MH1996GOI098009**

Logo:

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "**Losses**") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as **"MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.